L&T secures projects worth up to Rs 5,000 crore across India and the Middle East
In Andhra Pradesh, L&T has secured multiple contracts from the Andhra Pradesh Capital Region Development Authority (APCRDA) for projects in Amaravati: Andhra Pradesh Secretariat & HoD Offices: L&T will design and construct Towers 3 and 4, each comprising a basement, ground floor, and 39 upper floors. The contract also includes the construction of an amenities building.
21 Residential Towers: The scope includes complete civil and architectural works—RCC shell and core, electricals, plumbing, sanitary fixtures, firefighting, lifts, DG sets, HVAC systems, and landscaping.
In Mumbai, Maharashtra, L&T has also secured a contract from a reputed developer to build two luxury residential towers. These skyscrapers will feature a 1B+1G+5P+59 floors configuration, rising up to 200 metres in height, with RCC shell and core works as the main scope. International Win in Oman
L&T's B&F division in Oman has received a repeat order from a prestigious client in Muscat. The project involves the construction of three identical premium office towers (G+8 floors) built above a shared two-level basement, complete with a landscaped central plaza. Scope of work includes civil, MEP, internal finishes for common areas, and external landscaping.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma. As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration. "This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond." NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates. "The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS. "This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS. The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. "The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options." About Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit Contact Tiberend Strategic Advisors, Inc. Jonathan Nugent (investors) +1-205-566-3026 jnugent@ Eric Reiss (media) ereiss@ View original content: SOURCE Elpis Biopharmaceuticals Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
AT&T Inc. (T) Is Very Good At What It Does, Says Jim Cramer
We recently published . AT&T Inc. (NYSE:T) is one of the stocks Jim Cramer recently discussed. AT&T Inc. (NYSE:T) has been performing well in 2025. Its shares gained 22.7% year-to-date on the back of multiple factors such as robust subscriber additions. The stock gained 2% after the latest earnings report, which saw AT&T Inc. (NYSE:T) add 401,000 wireless subscribers to smash analyst estimates of 295,700 out of the park. The firm's strong performance made Cramer wonder how all three mega American carriers could simultaneously perform well, as logically, someone has to lose share for the others to thrive: 'But David, AT&T, has someone downgraded AT&T? I thought that AT&T was good. But how can AT&T and Verizon and T-Mobile do well? Cramer recently discussed AT&T Inc. (NYSE:T)'s stock in comparison to T-Mobile: 'You know, people like ATT. And I'm not against it. I like ATT, too. But, look what can I say, T-Mobile has been a huge, huge winner. Sievert is a winner. And before that Legere was a winner. But now the stock acts quite badly, and now we know. It's good to know the reason.' While we acknowledge the potential of T as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
T-Mobile US, Inc. (TMUS) Is Very Good At What It Does, Says Jim Cramer
We recently published . T-Mobile US, Inc. (NASDAQ:TMUS) is one of the stocks Jim Cramer recently discussed. T-Mobile US, Inc. (NASDAQ:TMUS) is an American telecommunications carrier whose shares have gained 10.9% year-to-date. The shares jumped by 6.1% in July after the firm's latest earnings report saw its $21.13 billion in revenue and $2.84 in EPS beat analyst estimates of $21.04 billion and $2.68. Another reason why T-Mobile US, Inc. (NASDAQ:TMUS)'s shares rose was due to its 830,000 postpaid additions beating analyst estimates of 700,300. Here's what Cramer said: 'That was a nice quarter. Previously, Cramer discussed T-Mobile US, Inc. (NASDAQ:TMUS)'s share price movements: 'Here's one [that's] a little surprising. Keybanc puts out a very cogent piece about how T-Mobile is fiber-deficient. And they think that the consumer value proposition has deteriorated rather rapidly. Downgraded to Underweight. And the stock has been weak. But this is a, in many ways you read this and you think oh my bad, now I know why it's going down. Which will mean that it's got much further to fall. While we acknowledge the potential of TMUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
